It is time to use treponema-specific antibody screening tests for diagnosis of syphilis

Michael J. Loeffelholz, Matthew J. Binnicker

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Assays that detect treponema-specific antibodies, which are either automated or can be done as point-of-care tests, have been developed, some of which are FDA approved. These assays have the advantage of being easily performed and demonstrate high sensitivity, both key features of an infectious disease screening test. As a result, many high-volume clinical laboratories have begun to offer a reverse syphilis testing algorithm where a treponema-specific test is used for screening, followed by a nontreponemal test (i.e., rapid plasma reagin [RPR]) to assess disease activity and treatment status. Concerns about physicians being able to understand and apply this new testing algorithm have been expressed (8). In this point-counterpoint, Michael Loeffelholz of the University of Texas Medical Branch at Galveston explains why his laboratory has adopted this reverse algorithmic approach. Matthew Binnicker of the Mayo Clinic, Rochester, MN, explains why the reverse algorithm may not be suitable for all clinical laboratories and every clinical situation.

Original languageEnglish (US)
Pages (from-to)2-6
Number of pages5
JournalJournal of Clinical Microbiology
Volume50
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Treponema
Syphilis
Antibodies
Point-of-Care Systems
Reagins
Communicable Diseases
Physicians
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

It is time to use treponema-specific antibody screening tests for diagnosis of syphilis. / Loeffelholz, Michael J.; Binnicker, Matthew J.

In: Journal of Clinical Microbiology, Vol. 50, No. 1, 01.2012, p. 2-6.

Research output: Contribution to journalArticle

Loeffelholz, Michael J. ; Binnicker, Matthew J. / It is time to use treponema-specific antibody screening tests for diagnosis of syphilis. In: Journal of Clinical Microbiology. 2012 ; Vol. 50, No. 1. pp. 2-6.
@article{41ce35d2acf1499e8e36b2395461276f,
title = "It is time to use treponema-specific antibody screening tests for diagnosis of syphilis",
abstract = "Assays that detect treponema-specific antibodies, which are either automated or can be done as point-of-care tests, have been developed, some of which are FDA approved. These assays have the advantage of being easily performed and demonstrate high sensitivity, both key features of an infectious disease screening test. As a result, many high-volume clinical laboratories have begun to offer a reverse syphilis testing algorithm where a treponema-specific test is used for screening, followed by a nontreponemal test (i.e., rapid plasma reagin [RPR]) to assess disease activity and treatment status. Concerns about physicians being able to understand and apply this new testing algorithm have been expressed (8). In this point-counterpoint, Michael Loeffelholz of the University of Texas Medical Branch at Galveston explains why his laboratory has adopted this reverse algorithmic approach. Matthew Binnicker of the Mayo Clinic, Rochester, MN, explains why the reverse algorithm may not be suitable for all clinical laboratories and every clinical situation.",
author = "Loeffelholz, {Michael J.} and Binnicker, {Matthew J.}",
year = "2012",
month = "1",
doi = "10.1128/JCM.06347-11",
language = "English (US)",
volume = "50",
pages = "2--6",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - It is time to use treponema-specific antibody screening tests for diagnosis of syphilis

AU - Loeffelholz, Michael J.

AU - Binnicker, Matthew J.

PY - 2012/1

Y1 - 2012/1

N2 - Assays that detect treponema-specific antibodies, which are either automated or can be done as point-of-care tests, have been developed, some of which are FDA approved. These assays have the advantage of being easily performed and demonstrate high sensitivity, both key features of an infectious disease screening test. As a result, many high-volume clinical laboratories have begun to offer a reverse syphilis testing algorithm where a treponema-specific test is used for screening, followed by a nontreponemal test (i.e., rapid plasma reagin [RPR]) to assess disease activity and treatment status. Concerns about physicians being able to understand and apply this new testing algorithm have been expressed (8). In this point-counterpoint, Michael Loeffelholz of the University of Texas Medical Branch at Galveston explains why his laboratory has adopted this reverse algorithmic approach. Matthew Binnicker of the Mayo Clinic, Rochester, MN, explains why the reverse algorithm may not be suitable for all clinical laboratories and every clinical situation.

AB - Assays that detect treponema-specific antibodies, which are either automated or can be done as point-of-care tests, have been developed, some of which are FDA approved. These assays have the advantage of being easily performed and demonstrate high sensitivity, both key features of an infectious disease screening test. As a result, many high-volume clinical laboratories have begun to offer a reverse syphilis testing algorithm where a treponema-specific test is used for screening, followed by a nontreponemal test (i.e., rapid plasma reagin [RPR]) to assess disease activity and treatment status. Concerns about physicians being able to understand and apply this new testing algorithm have been expressed (8). In this point-counterpoint, Michael Loeffelholz of the University of Texas Medical Branch at Galveston explains why his laboratory has adopted this reverse algorithmic approach. Matthew Binnicker of the Mayo Clinic, Rochester, MN, explains why the reverse algorithm may not be suitable for all clinical laboratories and every clinical situation.

UR - http://www.scopus.com/inward/record.url?scp=84555189809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84555189809&partnerID=8YFLogxK

U2 - 10.1128/JCM.06347-11

DO - 10.1128/JCM.06347-11

M3 - Article

C2 - 22090405

AN - SCOPUS:84555189809

VL - 50

SP - 2

EP - 6

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 1

ER -